By combining these markers with others that evaluate different pathophysiological pathways associated with stroke such as IL-6 and D-dimer, we can develop a comprehensive panel of blood biomarkers that may provide a more accurate clinical prognosis for stroke patients with prediabetes and T2DM. The gene discussed is IL6; the disease is prediabetes syndrome.